» Articles » PMID: 38404852

Prevalence of Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention at a Tertiary Referral Hospital

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Feb 26
PMID 38404852
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aimed to quantify the incidence of Contrast-induced nephropathy (CIN) in patients undergoing primary percutaneous coronary intervention (PPCI) due to acute ST-elevation myocardial infarction (STEMI).

Methods: From April 2019 to March 2022, a prospective, observational study enrolled 213 consecutive STEMI patients referred to a tertiary hospital for PPCI. Participants were divided into tow groups based on the presence or absence of contrast-induced nephropathy. The chi-square test (χ2) and Student's t-test evaluated the data, with logistic regression identifying CIN's independent predictors.

Results: Results: In this study, the incidence of contrast-induced nephropathy was observed at 13.1% (N = 28). Several factors were more prevalent among patients exhibiting contrast-induced nephropathy. These factors encompassed: radial access for coronary angiography over the femoral method (P = 0.021), elevated contrast volume (P = 0.003), smoking (P = 0.009), diabetes (P = 0.04), heart failure (P = 0.049), a history of coronary artery bypass graft (P = 0.006), diminished left ventricular ejection fraction indicating systolic dysfunction (P = 0.012), cardiogenic shock (P = 0.046), increased BUN at the time of admission (P = 0.043), decreased initial GFR (P = 0.004), and prior consumption of medications such as aspirin (P = 0.002), diuretics (P = 0.046), beta blockers (P = 0.04), angiotensin-converting enzyme inhibitors (P = 0.033), angiotensin receptor blockers (P = 0.02). Other relevant conditions included anemia (P = 0.012), leukocytosis (P = 0.011), hypercholesterolemia (P = 0.034), and reduced HDL levels (P = 0.004).Through logistic regression, key predictors for the onset of contrast-induced nephropathy were determined, which included heart failure (OR: 5.52; 95% CI: 1.08-28.24), radial access (OR: 12.71; 95% CI: 1.45-110.9), hypercholesterolemia (OR: 1.02; 95% CI: 1.004-1.04), increased BUN upon admission (OR: 1.11; 95% CI: 1.006-1.24), and leukocytosis (OR: 2.03; 95% CI: 1.18-3.49).

Conclusions: While heart failure, radial access, hypercholesterolemia, elevated BUN at admission, and leukocytosis significantly influenced renal filtration deterioration post-PPCI, it's evident that CIN is multifactorial. Further studies are crucial to elucidate the underlying factors.

Citing Articles

The Impact of Insulin Resistance on the Development of Post-PCI Contrast-Induced Nephropathy in Non-Diabetic STEMI.

Mete Yildirim A, Bayramoglu A Acta Cardiol Sin. 2025; 41(1):130-137.

PMID: 39776926 PMC: 11701499. DOI: 10.6515/ACS.202501_41(1).20241018B.

References
1.
Katsogridakis E, Lea T, Yap T, Batchelder A, Saha P, Diamantopoulos A . Acute kidney injury following endovascular intervention for peripheral artery disease. Br J Surg. 2021; 108(2):152-159. PMC: 7954277. DOI: 10.1093/bjs/znaa057. View

2.
Borekci A, Gur M, Turkoglu C, Cayli M, Selek S, Kaypakli O . Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2014; 66(4):339-45. DOI: 10.1177/0003319714533588. View

3.
Cinar T, Keskin M, Kaya A . Atrial Fibrillation: A New Risk Factor for Contrast-Induced Nephropathy. Angiology. 2018; 70(5):470. DOI: 10.1177/0003319718802906. View

4.
Ando G, Costa F, Trio O, Oreto G, Valgimigli M . Impact of vascular access on acute kidney injury after percutaneous coronary intervention. Cardiovasc Revasc Med. 2016; 17(5):333-8. DOI: 10.1016/j.carrev.2016.03.004. View

5.
Levine G, Bates E, Blankenship J, Bailey S, Bittl J, Cercek B . 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline.... J Am Coll Cardiol. 2015; 67(10):1235-1250. DOI: 10.1016/j.jacc.2015.10.005. View